Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $7.54 up 2.72% from its previous closing price of $7.34. In other words, the price has increased by $2.72 from its previous closing price. On the day, 0.95 million shares were traded. DNA stock price reached its highest trading level at $7.6472 during the session, while it also had its lowest trading level at $7.18.
Ratios:
For a deeper understanding of Ginkgo Bioworks Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.62 and its Current Ratio is at 5.62. In the meantime, Its Debt-to-Equity ratio is 0.65 whereas as Long-Term Debt/Eq ratio is at 0.61.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 22 ’25 when Che Austin bought 99 shares for $7.49 per share.
Dmytruk Mark E. bought 1,244 shares of DNA for $9,060 on Apr 21 ’25. On Apr 21 ’25, another insider, Che Austin, who serves as the Officer of the company, bought 99 shares for $7.50 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 437573344 and an Enterprise Value of 316103008. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.93 while its Price-to-Book (P/B) ratio in mrq is 0.54. Its current Enterprise Value per Revenue stands at 1.392 whereas that against EBITDA is -0.76.
Stock Price History:
The Beta on a monthly basis for DNA is 0.98, which has changed by -0.77718675 over the last 52 weeks, in comparison to a change of 0.042615533 over the same period for the S&P500. Over the past 52 weeks, DNA has reached a high of $45.20, while it has fallen to a 52-week low of $5.00. The 50-Day Moving Average of the stock is -9.63%, while the 200-Day Moving Average is calculated to be -19.10%.
Shares Statistics:
For the past three months, DNA has traded an average of 1.72M shares per day and 1608050 over the past ten days. A total of 42.70M shares are outstanding, with a floating share count of 36.98M. Insiders hold about 32.80% of the company’s shares, while institutions hold 59.33% stake in the company. Shares short for DNA as of 1743379200 were 11395098 with a Short Ratio of 6.63, compared to 1740700800 on 9062852. Therefore, it implies a Short% of Shares Outstanding of 11395098 and a Short% of Float of 33.62.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $38.7M this quarter.It ranges from a high estimate of $40.5M to a low estimate of $37M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $37.94MFor the next quarter, 5 analysts are estimating revenue of $43.74M. There is a high estimate of $45.5M for the next quarter, whereas the lowest estimate is $41.8M.
A total of 6 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $179M, while the lowest revenue estimate was $169.7M, resulting in an average revenue estimate of $173.04M. In the same quarter a year ago, actual revenue was $227.04MBased on 5 analysts’ estimates, the company’s revenue will be $201.9M in the next fiscal year. The high estimate is $250M and the low estimate is $178.74M.
